EGFR and neoplasm: Based on the “tumor cells repopulation” hypothesis, several clinical phenomenons were reported, including the restoration of EGFR-TKI sensitivity after EGFR-TKI withdrawal [15], disease flare after discontinuation of EGFR-TKI [20], and a better outcome for T790M-mutant patients [17].